Money on the table

Sofinnova Partners and NEA turned a tidy profit from last week's sale of Omthera Pharmaceuticals Inc. (NASDAQ:OMTH) to AstraZeneca plc (LSE:AZN; NYSE:AZN), though it might have been tidier still had the offer come before Omthera's IPO in April.